Current and potential uses of imiquimod

Southern Medical Journal

Volumn 98, Issue 9, 2005, Pages 914-920

  Chang, Yuchi C ^b   Madkan, Vandana ^b   Cook Norris, Robert ^b   Sra, Karan ^b   Tyring, Stephen ^a  

^a University of Texas Health Science Center at Houston   (United States)

^b NONE

Author keywords

Antitumor; Antiviral; Imiquimod; Immune response modifier

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD; INTERLEUKIN 12; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BASAL CELL CARCINOMA; BOWEN DISEASE; BOWENOID PAPULOSIS; COMBINATION CHEMOTHERAPY; CONDYLOMA; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG POTENCY; DRUG USE; ERADICATION THERAPY; FOOD AND DRUG ADMINISTRATION; GRANULOMA ANNULARE; HEMANGIOMA; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; KELOID; KERATOACANTHOMA; LEISHMANIASIS; MALIGNANT LENTIGO; MELANOMA; MOLLUSCUM CONTAGIOSUM; MORPHEA; PAGET SKIN DISEASE; POROKERATOSIS MIBELLI; REVIEW; SKIN DISEASE; SYSTEMATIC REVIEW; TATTOOING; VULVA TUMOR;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; NEOPLASMS; SKIN DISEASES; TATTOOING;

EID: 25844505692     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000176712.01491.98     Document Type: Review

References (43)

1. 3M Pharmaceuticals. Aldara TM (imiquimod) Cream, 5% (Package Insert). 2004.
2. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2000;3:196-200.
3. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999;21:1-14.
4. Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003; 121:1205-1209.
5. Edwards L, Ferencz A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134:25-30.
6. Drug Information for the Health Care Professional. MICROMEDEX Thompson Healthcare; 2002.
7. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratoses: results form two phase III trials, randomized, double blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-721.
8. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498-502.
9. Stockfleth E, Christophers E, Benninghoff B, et al. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004;140:1542.
10. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol 2002;47:571-577.
11. American Cancer Society. Cancer facts and figures 2004. Available at: http://www.cancer.org. Accessed March 2005.
12. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinomas: results form two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50: 722-733.
13. Smith KJ, Germain M, Yeager J, et al. Topical 5% imiquimod for the therapy of actinic cheilitis. J Am Acad Dermatol 2002;47:497-501.
14. Mackenzie-Wood A, Kossard S, de Launey, J, et al. Imiquimod 5% cream in the treatment of Bowen disease. J Am Acad Dermatol 2001; 44:462-470.
15. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001;27:561-564.
16. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002;138:1165-1171.
17. Huber A, Huber JD, Skinner RB, et al. Topical imiquimod for nodular basal cell carcinomas: an open label series. Dermatol Surg 2004;30:429-430.
18. Torres A, Niemeyer A, Berkes B, et al. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg 2004;30:1462-1469.
19. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003;149 (Suppl 66):66-69.
20. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004; 29:15-21.
21. Ugurel S, Wagner A, Pfohler C, et al. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002;147:621-624.
22. Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003;139:273-276.
23. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier, imiquimod. Arch Dermatol 2002;138:1137-1139.
24. Joura EA, Losch A, Haider-Angeler MG, et al. Trends in vulvar neoplasia: Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 2000;45:613-615.
25. van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3: Results of a pilot study. J Reprod Med 2003;47:701-705.
26. Zampogna JC, Flowers FP, Roth WI, et al. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 2002;47:S229-S235.
27. Berman B, Spencer J, Villa A, et al. Successful treatment of extramammary Paget's disease of the scrotum with imiquimod 5% cream. Clin Exp Dermatol 2003;28(Suppl 1):36-38.
28. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337: 1105-1111.
29. Gilbert J, Drehs MM, Weinberg JM. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol 2001;137: 1015-1017.
30. Schaker TW, Conant M, Thoming C, et al. Imiquimod 5% cream does not alter the natural history of recurrent herpes genitalis: a phase 2, randomized, double blind, placebo controlled study. Antimicrob Agents Chemother 2002;46:3242-3248.
31. Bayerl C, Feller G, Goerdt S. Experience in treating molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol 2003; 149(Suppl 66):25-29.
32. Ross GL, Orchard DC. Combination topical treatment of molluscum contagiosum with cantharidin and imiquimod 5% in children: a case series of 16 patients. Australas J Dermatol 2004;45:100-102.
33. Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol 1999;135:1167-1169.
34. Richter ON, Petro W, Wardelmann E, et al. Bowenoid papulosis of the vulva-immunotherapeutical approach with topical imiquimod. Arch Gynecol Obstet 2003;268:333-336.
35. Stockfleth E, Rowert J, Arndt R, et al. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br J Dermatol 2000;143:846-850.
36. Agarwal S, Berth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br J Dermatol 2001;146:338-339.
37. Kuwahara RT, Naylor MF, Skinner RB. Treatment of granuloma annulare with topical 5% imiquimod cream. Pediatr Dermatol 2003;20:90.
38. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002;47(Suppl 4):S209-S11.
39. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-1851.
40. Solis RR, Diven DG, Colome-Grimmer MI, et al. Experimental nonsurgical tattoo removal in a guinea pig model with topical imiquimod and tretinoin. Dermatol Surg 2002;28:83-86.
41. Man J, Dytoc MT. Use of imiquimod 5% cream in the treatment of localized morphea. J Cutan Med Surg 2004;8:166-169.
42. Martinez MI, Sanchez-Carpintero I, North PE, et al. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002; 138:881-884.
43. Dendorfer M, Oppel T, Wollenberg A, et al. Topical treatment with imiquimod may induce regression of facial keratoacanthoma Eur J Dermatol 2003;13:80-82.